Recent Posts tagged as 'CBD'
Blog Post
07/24/2020
By Jonathan A. Havens

It has been a busy summer for the cannabis and cannabis-derived products spaces. This month alone, the U.S. Food and Drug Administration (FDA or the Agency): (1) sent to the White House Office of Management and Budget (OMB) for review a “Cannabidiol Enforcement Policy” draft guidance; (2) announced the availability of another draft guidance, “Cannabis and Cannabis-Derived Compounds: Quality Considerations for Clinical Research”; and (3) made public its report to Congress, “Sampling Study of the Current Cannabidiol Marketplace to Determine the Extent That Products are Mislabeled or Adulterated.”

Blog Post
11/26/2019
By Jonathan A. Havens

On November 25, 2019, the U.S. Food and Drug Administration (FDA or the Agency) announced that it had issued Warning Letters to 15 companies for illegally selling products containing cannabidiol (CBD).

Blog Post
10/29/2019
By Jonathan A. Havens

On October 29, 2019, the U.S. Department of Agriculture (USDA) issued a pre-publication version of its long awaited hemp production interim final rule. Public comments are due 60 days after USDA publishes the rule in the Federal Register.

Blog Post
08/13/2019
By Jonathan A. Havens and Ruth A. Rauls

On August 9, 2019, New Jersey Governor Phil Murphy signed A5322 into law, making the Garden State the latest to establish a permanent program for the cultivation, handling, processing, transport, and sale of hemp and hemp-derived products.

Blog Post
05/06/2019
By Jonathan A. Havens and Casey Grabenstein

Although hemp is now federally legal, as a result of the enactment of the Agriculture Improvement Act of 2018 (the 2018 Farm Bill) late last year, the Alcohol and Tobacco Tax and Trade Bureau (TTB) recently declared that adding hemp-derived cannabidiol (CBD) to alcohol beverages is impermissible.

Blog Post
04/04/2019
By Jonathan A. Havens

On April 2, 2019, outgoing U.S. Food and Drug Administration (FDA or the Agency) Commissioner Scott Gottlieb, M.D., further addressed FDA’s approach to cannabis-containing and cannabis-derived products (e.g., cannabidiol (CBD)-containing products).